GlassScriptPhysician profile
Mark W Gustafson
NPI 1134108756
$2,618.88
in general payments reported to CMS, 2019-2025
27 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $141 · 2021: $247 · 2022: $673 · 2023: $613 · 2024: $280 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.51 | 2019-2023 | |
| Astellas Pharma US INC | $371.06 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $259.03 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $211.30 | 2023-2025 | Gemtesa, Myfembree |
| Amgen INC. | $187.00 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $185.06 | 2019-2024 | |
| Urovant Sciences INC | $179.95 | 2021-2022 | |
| Coopersurgical, INC. | $131.29 | 2019-2023 | Endosee |
| Organon LLC | $114.99 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $62.63 | 2019-2024 | Gardasil 9, Gardasil |
| Tactile Systems Technology INC | $56.18 | 2022 | |
| Hologic Sales and Service, LLC | $53.92 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Myovant Sciences INC. | $49.21 | 2022 | |
| Exeltis, USA INC. | $45.63 | 2022-2024 | Nuvessa, Slynd |
| Therapeuticsmd, INC. | $40.72 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $22.77 | 2024 | |
| Dexcom, INC. | $22.37 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $22.18 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $21.70 | 2020 | |
| Biogen, INC. | $21.24 | 2025 | Zurzuvae |
| Coloplast Corp | $19.58 | 2019 | |
| Convatec INC. | $19.13 | 2022 | |
| Aspira Women'S Health INC | $18.47 | 2023 | Ova1 |
| Mayne Pharma Commercial LLC | $17.84 | 2023 | |
| Si-Bone, INC. | $16.04 | 2024 | |
| Shire North American Group INC | $15.82 | 2019 | |
| Minerva Surgical, INC | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.